Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300
Debt
Debt-to-Equity Ratio0.77
Current Ratio0.56
Quick Ratio0.33
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.36 million
Price / Sales7.45
Cash FlowN/A
Price / CashN/A
Book Value$2.46 per share
Price / Book0.27
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-21,960,000.00
Net Margins-663.76%
Return on Equity-116.52%
Return on Assets-48.98%
Miscellaneous
Employees36
Outstanding Shares49,830,000
Market Cap$28.80 million
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health Inc (NASDAQ:JAGX) issued its earnings results on Monday, November, 14th. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.10. The biotechnology company earned $0.05 million during the quarter, compared to analysts' expectations of $0.10 million. Jaguar Health had a negative return on equity of 116.52% and a negative net margin of 663.76%. View Jaguar Health's Earnings History.
When is Jaguar Health's next earnings date?
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include BIOLINERX Ltd/S (BLRX), OASMIA PHARMACE/ADR (OASM), Northwest Biotherapeutics (NWBO), Aerpio Pharmaceuticals (ARPO), Oncolytics Biotech (ONCYF), Arcturus Therapeutics (ARCT), Aridis Pharmaceuticals (ARDS), Vaccinex (VCNX), Leap Therapeutics (LPTX), Vernalis (VNLPY), Evofem Biosciences (EVFM), XBiotech (XBIT), Iterum Therapeutics (ITRM), Scpharmaceuticals (SCPH) and GT Biopharma (GTBP).
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, CEO, Pres & Director (Age 59)
- Ms. Karen S. Wright, CFO & Treasurer (Age 62)
- Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 60)
- Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 55)
- Mr. Pete Riojas, National Sales Director
When did Jaguar Health IPO?
(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
Who are Jaguar Health's major shareholders?
Jaguar Health's stock is owned by many different of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (1.14%). Company insiders that own Jaguar Health stock include Jonathan B Siegel and Lisa A Conte. View Institutional Ownership Trends for Jaguar Health.
Which major investors are buying Jaguar Health stock?
JAGX stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Company insiders that have bought Jaguar Health stock in the last two years include Jonathan B Siegel and Lisa A Conte. View Insider Buying and Selling for Jaguar Health.
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $0.6520.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $28.80 million and generates $4.36 million in revenue each year. Jaguar Health employs 36 workers across the globe.
What is Jaguar Health's official website?
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
